



GERRESHEIMER

Deutsche Bank

German & Austrian Corporate Conference

Frankfurt, May 19 & 20, 2011

Uwe Röhrhoff, CEO

Disclaimer

- This presentation may contain certain forward-looking statements, including assumptions, opinions and views of the Company or cited from third party sources. Various known and unknown risks, uncertainties and other factors could cause the actual results, financial position, development or performance of the Company to differ materially from the estimations expressed or implied herein.
- The Company does not guarantee that the assumptions underlying such forward-looking statements are free from errors nor does the Company accept any responsibility for the future accuracy of the opinions expressed in this presentation or the actual occurrence of the forecast development.
- No representation or warranty (express or implied) is made as to, and no reliance should be placed on, any information, including projections, estimates, targets and opinions, contained herein, and no liability whatsoever is accepted as to any errors, omissions or misstatements contained herein, and, accordingly, none of the Company or any of its parent or subsidiary undertakings or any of such person's officers, directors or employees accepts any liability whatsoever arising directly or indirectly from the use of this document.

Agenda

1 Company description

2 Appendix

Gerresheimer at a glance

Key facts

- Leading international manufacturer high-quality specialty products made of glass and plastic for the global pharma and healthcare industry
- Whole range of pharmaceutical products enable easy drug administration



1) Financial year ends on 30 November

Clear focus on pharma and healthcare

82%


Pharma and
Healthcare

12%

Cosmetics

6%

Other



Organizational structure

Consolidated net revenues FY 2010: EUR 1,024.8m

Tubular Glass



EUR 310.4m
30% of total revenues

Plastic Systems




EUR 307.9m
30% of total revenues

Moulded Glass




EUR 327.3m
31% of total revenues

Life Science Research



EUR 95.0m
9% of total revenues

Gerresheimer is a leading global player



**Europe & North America most important,
pharmerging markets gaining in significance**

63%

Europe (23% Germany)

24%

North America

13%

Other regions



Highly attractive end market trends

- Aging of world population
- Development of healthcare systems in emerging countries
- Growing number of acute and chronic diseases
- Accelerating pace in drug development
- Growth in biotech drugs and generics
- Outsourcing trend of drug delivery and primary packaging solutions
- Trend towards self-medication

Well-diversified blue-chip customer base

Pharma and healthcare




Other



Gerresheimer has close long-term relationships with leading global accounts...

Net revenues to TOP 50 customers (FY 2010) in EUR m



...with limited dependence on individual customers.

Leading market positions in attractive niche markets

Division	Tubular Glass (Injectable Glass and Systems)			Plastic Systems (Plastic Drug Delivery and Systems)				Moulded Glass	Life Science Research
	Tubing	Syringes	Other Injectables	Plastic Packaging	Inhalation (DPI) ¹	Diabetes Diagnostics ²	Pens	Pharma (Type I)	Glass Consumables & Equipment
Europe	# 2	# 2	# 2	# 1	# 1	# 2	started	# 2	
North America	# 1	# 2	# 1		# 3			# 1	# 1
Emerging Markets		# 2 (China)	# 1 (China)	# 1 (South America)			started (South America)		# 1 (China)

1) DPI = Dry Powder Inhaler

2) Includes lancets and lancing devices only

Source: Company estimates

Gerresheimer provides solutions across all key product categories


Division	Tubular Glass (Injectable Glass and Systems)			Plastic Systems (Plastic Drug Delivery and Systems)				Moulded Glass		Life Science Research
	Glass Tubing	Syringes	Other Injectables	Inhalers	Plastic Packaging	Diabetes Diagnostics ²	Pens	Pharma (Type I)	OTC liquids and Syrups (Type II & III)	Glass Consumables & Equipment
Gerresheimer	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
Schott	✓	✓	✓							
Becton Dickinson ¹		✓				✓				
Amcor Alcan ¹	✓		✓		✓					
Ompi		✓	✓							
Nypro				✓	✓	✓	✓			
Consort Medical ¹				✓						
West Pharma ¹					✓		✓			
Rexam ¹				✓	✓		✓			
Facet						✓				
Ypsomed ¹							✓			
Desjonquères								✓	✓	
Rocco Bormioli					✓			✓	✓	
Duran										✓
Corning ¹										✓

1) Public company

2) Includes lancets and lancing devices only


Source: Company estimates

Gerresheimer's strategy



Strong operational performance in financial year 2010

Key group figures (EUR m)




1) The Technical Plastic Systems ("TPS") business was sold with effect from July 1, 2009

2) Revenue growth for FY 2010 and adjusted EBITDA / adjusted EBITDA margin for FY2009 are shown excluding TPS


Strong improvement of financial ratios in 2010

Key financial ratios/figures

Net debt¹ / adjusted EBITDA




Capital expenditure (EUR m)




Metric	2009	2010
Capex / Revenues	8.6%	7.1%

Equity ratio



Net working capital² (EUR m)







Metric	2009	2010
NWC / Revenues	18.2%	17.3%

1) Total amount of debt less cash and cash equivalents

2) Average net working capital: Inventories (incl. prepayments) and trade receivables less trade payables and payments received on account of orders

Good start to the financial year 2011

Key group figures (EUR m)



Vedat acquisition in April 2011 more than doubles revenues in South America

Current setup in South America

- Since 2007/2008
 - 3 plants in Sao Paulo
 - 1 plant in Buenos Aires
 - 500 employees
-
- Main products
 - plastic containers
 - insulin pens



Vedat

Embu, Sao Paulo, Brazil



- Founded in 1962
 - 450 employees
 - 2010 revenues approx. EUR 45m
 - Clean room facilities
-
- Main Products
 - closures
 - plastic containers
 - PET bottles

Gerresheimer Plastic Systems – Providing full service in South America

The established Gerresheimer Plastic Systems products



The expanded portfolio – Vedat's additional products



Guidance FY 2011 update reflects inclusion of Vedat acquisition

	FY 2010 as reported	Guidance FY 2011 As of Feb. 10, 2011	Guidance FY 2011 As of April 7, 2011
Net revenues	EUR 1,024.8m	+3% to 4% at const. FX	+6% to 7% at const. FX
Adj. EBITDA margin	20.0%	About 20.0%	About 20.0%
Capex	EUR 73.2m	About EUR 80m	About EUR 80m

Agenda

1 Company description

2 Appendix

Q1 2011 P&L overview

	Q1 2011 EUR m	Q1 2010 EUR m	Change in %
Total revenues	236.6	224.8	+5.2
Adjusted EBITDA ¹	41.8	38.3	+9.0
EBITA	21.5	18.6	+15.6
Amortization of FV adjustments	4.7	6.3	-25.4
Profit before interest and taxes (EBIT)	16.8	12.3	+36.6
Financial result	-6.9	-8.9	+22.5
Profit before taxes	9.9	3.4	>100
Net income	7.1	2.4	>100
EPS in EUR	0.20	0.06	>100
Adjusted EPS in EUR ²	0.30	0.22	+36.4

¹ Earnings before financial result, income taxes, amortization of fair value adjustments, extraordinary depreciation, depreciation and amortization, restructuring expenses and one-off income and expenses

² Adjusted net income after non-controlling interests divided by 31.4m shares

Q1 2011: Revenues by division

	Q1 2011		
	EUR m	Change in %	Change in % at const. FX
Total Group	236.6	+5.2	+2.9
Tubular Glass	66.8	-5.8	-8.1
Plastic Systems	72.1	+11.4	+8.8
Moulded Glass	80.3	+10.9	+9.8
Life Science Research	21.3	+4.3	-1.4

Q1 2011: Adjusted EBITDA¹ and margin by division

	Q1 2011			Q1 2010
	EUR m	Change in %	Margin	Margin
Total Group	41.8	+9.0	17.7	17.0
Tubular Glass	13.8	-16.8	20.6	23.4
Plastic Systems	14.4	+7.3	20.0	20.7
Moulded Glass	16.1	+36.6	20.1	16.3
Life Science Research	2.2	+24.3	10.4	8.8

¹ Earnings before financial result, income taxes, amortization of fair value adjustments, extraordinary depreciation, depreciation and amortization, restructuring expenses and one-off income and expenses

Key financial figures

	February 28, 2011 EUR m	February 28, 2010 EUR m	Change in %
Equity	536.7	482.6	+11.2
<i>Equity ratio in %</i>	40.2	35.9	
Net Working Capital ¹	172.3	175.1	-1.6
<i>in % of LTM revenues</i>	16.6	17.7	
Net Financial Debt ²	318.2	402.6	-21.0
Adjusted EBITDA leverage	1.5	2.2	-31.8
	Q1 2011 EUR m	Q1 2010 EUR m	Change in %
Capital expenditure	9.7	15.9	-39.0
Free cash flow	-13.8	-13.2	-4.5

¹ Inventories (incl. prepayments) and trade receivables less trade payables and payments received on account of orders

² Total amount of debt less cash and cash equivalents

Reconciliation from adjusted EBITDA to net income

EUR m	FY 2009	FY 2010
Adjusted EBITDA	185.9	204.5
Restructuring expenses	3.6	3.7
One-off income/expense	2.0	0.0
EBITDA	180.3	200.8
Amortization of fair value adjustments	38.3	24.8
Depreciation	76.2	81.0
Book loss from disinvestment	5.3	0.0
Result from operations	60.5	95.0
Financial result	-40.3	-34.3
Income taxes	-13.2	-14.0
Net income	7.0	46.7
Attributable to non-controlling interests	1.2	3.5
Attributable to GX shareholders	5.8	43.2
Adjusted net income	45.2	65.8

Contact details: Investor & Creditor Relations

■ **Phone** +49 211 6181-257

■ **Fax** +49 211 6181-121

■ **E-mail** gerresheimer.ir@gerresheimer.com

■ **IR website** www.gerresheimer.com/ir